| | |
 |  | |
 | ||
 | | 
29-May-09
Update to Total Voting Rights more >> 22-May-09 Result of AGM more >> 20-May-09 Clinical Trial Update more >>  
AGM 2009 Presentation (PDF)
2008 Annual Report and AGM Notice (PDF) Quick Facts (PDF) AIM August 2006 Admission document (PDF) GECR Equity Research (PDF)   Subscribe to our Email List | |  Verona Pharma plc is a life sciences company dedicated to the research, discovery and development of new therapeutic drugs for the treatment of allergic rhinitis (hay fever) and other chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), as well as chronic inflammatory diseases. Verona Pharma currently has three potential drug treatments under development and continues to look for other possible drug development opportunities aimed at the respiratory and inflammatory diseases markets. Verona Pharma is incorporated in the United Kingdom and has its principal office in central London. Verona Pharma is traded on the AIM stock exchange under the symbol VRP. The information on this website is made available pursuant to AIM Rule 26. This website was last updated on 21 May 2009. | | |
| ||
| | |
| ||
| Home Company Information Products AIM Rule 26 News Releases Contact For Staff | |
| ©2006 Verona Pharma Plc All Rights Reserved. | Disclaimer | |